{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography+%28PET%29%2Fmagnetic+resonance+imaging+%28MRI%29&page=32",
    "query": {
      "intervention": "Positron emission tomography (PET)/magnetic resonance imaging (MRI)",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 1005,
    "total_pages": 101,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography+%28PET%29%2Fmagnetic+resonance+imaging+%28MRI%29&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography+%28PET%29%2Fmagnetic+resonance+imaging+%28MRI%29&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T03:36:34.197Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00662506",
      "title": "Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Diffusion Tensor Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Diffusion Weighted Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Perfusion Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2008-04",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662506"
    },
    {
      "nct_id": "NCT04219904",
      "title": "PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stage IA Cervical Cancer",
        "Stage IA1 Cervical Cancer",
        "Stage IA2 Cervical Cancer",
        "Stage IB Cervical Cancer",
        "Stage IB1 Cervical Cancer",
        "Stage IB2 Cervical Cancer",
        "Stage IB3 Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Gadobutrol",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2018-09-07",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04219904"
    },
    {
      "nct_id": "NCT01908504",
      "title": "Adaptive Pet Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Head and Neck Cancers",
        "Lung and Esophagus Cancers",
        "Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers"
      ],
      "interventions": [
        {
          "name": "PET-CT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 271,
      "start_date": "2012-01",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01908504"
    },
    {
      "nct_id": "NCT03582774",
      "title": "Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-labeled PSMA-11",
          "type": "RADIATION"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 193,
      "start_date": "2018-07-12",
      "completion_date": "2028-07-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • San Francisco, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582774"
    },
    {
      "nct_id": "NCT06871410",
      "title": "Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-CD83 CAR T-cells",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chest Radiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2026-02-02",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06871410"
    },
    {
      "nct_id": "NCT03242824",
      "title": "The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Fluorine F 18 Fluorodopa",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-09-29",
      "completion_date": "2021-06-16",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03242824"
    },
    {
      "nct_id": "NCT03463889",
      "title": "Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gallium Ga 68-labeled PSMA-11",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-03-19",
      "completion_date": "2020-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-06-29",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03463889"
    },
    {
      "nct_id": "NCT07087860",
      "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma",
        "Refractory Bladder Urothelial Carcinoma",
        "Refractory Renal Pelvis and Ureter Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v7",
        "Stage IV Renal Pelvis and Ureter Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Central Venous Cannula Insertion",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Antibody-Drug Conjugate Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-08-01",
      "completion_date": "2028-08-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07087860"
    },
    {
      "nct_id": "NCT06076538",
      "title": "PET/MR for Characterization of Renal Masses (RMs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Tumor",
        "Renal Cell Carcinoma",
        "Renal Tumor, Benign"
      ],
      "interventions": [
        {
          "name": "2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2023-08-01",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06076538"
    },
    {
      "nct_id": "NCT06589804",
      "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hypopharyngeal Squamous Cell Carcinoma",
        "Metastatic Laryngeal Squamous Cell Carcinoma",
        "Metastatic Oral Cavity Squamous Cell Carcinoma",
        "Metastatic Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Neck Squamous Cell Carcinoma of Unknown Primary",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Refractory Head and Neck Squamous Cell Carcinoma",
        "Refractory Hypopharyngeal Squamous Cell Carcinoma",
        "Refractory Laryngeal Squamous Cell Carcinoma",
        "Refractory Oral Cavity Squamous Cell Carcinoma",
        "Refractory Oropharyngeal Squamous Cell Carcinoma",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Hypopharyngeal Carcinoma AJCC v8",
        "Stage IV Laryngeal Cancer AJCC v8",
        "Stage IV Lip and Oral Cavity Cancer AJCC v8",
        "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2025-03-27",
      "completion_date": "2029-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-16T03:36:34.197Z",
      "location_count": 200,
      "location_summary": "Little Rock, Arkansas • Marysville, California • Palo Alto, California + 161 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Marysville",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06589804"
    }
  ]
}